Medicaid Pharmacy and Therapeutics Committee Agenda for May 9, 2007
The Pharmacy & Therapeutics Committee will meet May 9, 2007, from 8:00 a.m. to 4:45 p.m., Meeting Room 6, Concourse, Empire State Plaza, Albany, New York
The Pharmacy and Therapeutics Committee will re-review each therapeutic class subject to the Preferred Drug Program (PDP) on an annual basis. This meeting will be devoted to the annual re-review of the therapeutic classes detailed below. Therapeutic classes subject to the PDP not included on this agenda will be re-reviewed at a meeting later this year.
The Committee will review new clinical and financial information pertaining to the following therapeutic classes to determine preferred and non-preferred drugs in each class. The Committee will only consider clinical information which is new since the previous review of the therapeutic class. New clinical information may include: new drug or drug product information, new indications, new safety information or new comparative clinical trials. Those wishing to submit new clinical information must do so at least two (2) weeks prior to the date of the meeting or the Committee may not have ample time to review the information.
1. Therapeutic Class: Bisphosphonates-Oral (Previous review date March 9, 2006)
Drugs Affected:Actonel (risedronate), Actonel with Calcium (risedronate with calcium carbonate), Boniva (ibandronate), Fosamax (alendronate), Fosamax Plus D (alendronate plus cholecalciferol)
2. Therapeutic Class: Calcitonins-Nasal (Previous review date March 30, 2006)
Drugs Affected: Fortical (calcitonin-salmon), Miacalcin (calcitonin-salmon)
3. Therapeutic Class: ACE Inhibitors (Previous review date February 2, 2006)
Drugs Affected: Accupril (quinapril), Aceon (perindopril erbumine), Altace (ramipril), benazepril, Capoten (captopril), captopril, enalapril maleate, fosinopril, lisinopril, Lotensin (benazepril), Mavik (trandolapril), moexipril, Monopril (fosinopril), Prinivil (lisinopril), quinapril, trandolapril, Univasc (moexipril), Vasotec (enalapril maleate), Zestril (lisinopril)
4. Therapeutic Class: ACE Inhibitor/Diuretic Combinations (Previous review date February 2, 2006)
Drugs Affected: Accuretic (quinapril/hctz), benazepril/hctz, Capozide (captopril/hctz), captopril/hctz, enalapril maleate/hctz, fosinopril/hctz, lisinopril/hctz, Lotensin HCT (benazepril/hctz), Monopril HCT (fosinopril/hctz), Prinzide (lisinopril/hctz), Quinaretic (quinapril/hctz), quinapril/hctz, Uniretic (moexipril/hctz), Vaseretic (enalapril maleate/hctz), Zestoretic (lisinopril/hctz)
5. Therapeutic Class: Dihydropyridine Calcium Channel Blockers (Previous review date March 9, 2006)
Drugs Affected: Adalat CC (nifedipine CC), Afeditab CR (nifedipine CR), amlodipine, Cardene (nicardipine), Cardene SR (nicardipine SR), DynaCirc (isradipine), DynaCirc CR (isradipine CR), felodipine ER, isradipine, nicardipine HCl, Nifediac CC (nifedipine CC), Nifedical XL (nifedipine XL), nifedipine, nifedipine ER, nifedipine SA, Norvasc (amlodipine), Plendil (felodipine ER), Procardia (nifedipine), Procardia XL (nifedipine XL), Sular (nisoldipine)
6. Therapeutic Class: ACE Inhibitor/Calcium Channel Blocker (Previous review date March 9, 2006)
Drugs Affected: Lexxel (enalapril maleate/felodipine ER), Lotrel (benazepril/amlodipine besylate), Tarka (trandolapril/verapamil ER)
7. Therapeutic Class: Angiotensin Receptor Blockers (ARB) (Previous review date February 2, 2006)
Drugs Affected: Atacand (candesartan cilexetil), Avapro (irbesartan), Benicar (olmesartan medoxomil), Cozaar (losartan), Diovan (valsartan), Micardis (telmisartan), Teveten (eprosartan mesylate)
8. Therapeutic Class: ARB/Diuretic Combinations (Previous review date February 2, 2006)
Drugs Affected: Atacand HCT (candesartan cilexetil/hctz), Avalide (irbesartan/hctz), Benicar HCT (olmesartan medoxomil/hctz), Diovan HCT (valsartan/hctz), Hyzaar (losartan/hctz), Micardis HCT (telmisartan/hctz), Teveten HCT (eprosartan/hctz)
9. Therapeutic Class: Beta Blockers (Previous review date March 9, 2006)
Drugs Affected: acebutolol, atenolol, betaxolol, bisoprolol fumarate, Blocadren (timolol), Coreg (carvedilol), Coreg CR (carvedilol CR), Corgard (nadolol), Inderal (propranolol), Inderal LA (propranolol LA), Innopran XL (propranolol XL), Kerlone (betaxolol), labetalol, Levatol (penbutolol), Lopressor (metoprolol tartrate), metoprolol succinate XL, metoprolol tartrate, nadolol, pindolol, propranolol, Sectral (acebutolol), Tenormin (atenolol), timolol maleate, Toprol XL (metoprolol succinate XL), Trandate (labetalol), Zebeta (bisoprolol fumarate)
10. Therapeutic Class: Beta Blocker/Diuretic Combinations (Previous review date May 5, 2006)
Drugs Affected: atenolol/chlorthalidone, bisoprolol fumarate/HCTZ, Corzide (nadolol/bendroflumethiazide), Inderide (propranolol/HCTZ), Lopressor HCT (metoprolol tartrate/HCTZ), metoprolol tartrate/HCTZ, propranolol/HCTZ, Tenoretic (atenolol/chlorthalidone), Ziac (bisoprolol fumarate/HCTZ)
11. Therapeutic Class: HMG-CoA Reductase Inhibitors (Statins) (Previous review date March 30, 2006)
Drugs Affected: Advicor (lovastatin/niacin extended-release), Altoprev (lovastatin extended-release), Caduet (atorvastatin/amlodipine), Crestor (rosuvastatin), Lescol (fluvastatin), Lescol XL (fluvastatin XL), Lipitor (atorvastatin), lovastatin, Mevacor (lovastatin), Pravachol (pravastatin), pravastatin, Pravigard PAC (pravastatin/buffered aspirin), simvastatin, Vytorin (simvastatin/ezetimibe), Zocor (simvastatin)
12. Therapeutic Class: Long Acting Narcotics (Previous review date May 5, 2006)
Drugs Affected: Avinza (morphine sulfate ER), Duragesic (fentanyl), fentanyl, Kadian (morphine sulfate SR), morphine sulfate SR, MS Contin (morphine sulfate CR), Opana ER (oxymorphone ER), Oramorph SR (morphine sulfate SR), oxycodone HCl CR, Oxycontin (oxycodone HCl CR)
13. Therapeutic Class: Proton Pump Inhibitors (PPI) (Previous review date June 9, 2006)
Drugs Affected: Aciphex (rabeprazole), Nexium (esomeprazole), omeprazole, Prevacid (lansoprazole), Prevacid NapraPAC (lansoprazole/naproxen), Prilosec (omeprazole), Prilosec OTC (omeprazole), Protonix (pantoprazole), Zegerid (omeprazole)
14. Therapeutic Class: Sedative Hypnotics/Sleep Agents (Previous review date May 5, 2006)
Drugs Affected:Ambien (zolpidem), Ambien CR (zolpidem CR), chloral hydrate, Dalmane (flurazepam), Doral (quazepam), estazolam, flurazepam, Halcion (triazolam), Lunesta (eszopiclone), Prosom (estazolam), Restoril (temazepam), Rozerem (ramelteon), Somnote (chloral hydrate), Sonata (zaleplon), temazepam, triazolam, zolpidem
15. Therapeutic Class: Serotonin Receptor Agonists (Triptans) (Previous review date May 5, 2006)
Drugs Affected: Amerge (naratriptan), Axert (almotriptan), Frova (frovatriptan), Imitrex (sumatriptan) tablet/nasal/injection, Maxalt (rizatriptan) tablet/MLT, Relpax (eletriptan), Zomig (zolmitriptan) tablet/nasal/ZMT
16. Therapeutic Class: Intranasal Steroids (Previous review date March 30, 2006)
Drugs Affected: Beconase AQ (beclomethasone dipropionate), Flonase (fluticasone propionate), flunisolide, fluticasone propionate, Nasacort AQ (triamcinolone acetonide), Nasarel (flunisolide), Nasonex (mometasone furoate), Rhinocort Aqua (budesonide)
17. Therapeutic Class: Thiazolidinediones (Previous review date June 9, 2006)
Drugs Affected: Actos (pioglitazone), Actoplus met (pioglitazone/metformin), Avandia (rosiglitazone), Avandamet (rosiglitazone/metformin), Avandaryl (rosiglitazone/glimepiride), Duetact (pioglitazone/glimepiride)
18. Therapeutic Class: Triglyceride Lowering Agents (Previous review date March 30, 2006)
Drugs Affected: Antara (fenofibrate), fenofibrate, gemfibrozil, Lofibra (fenofibrate), Lopid (gemfibrozil), Omacor (Omega-3 acid ethyl esters), Tricor (fenofibrate), Triglide (fenofibrate)
19. Therapeutic Class: Ophthalmic Quinolones (Previous review date December 8, 2006)
Drugs Affected: Ciloxan solution/ointment (ciprofloxacin), ciprofloxacin, Ocuflox (ofloxacin), ofloxacin, Quixin (levofloxacin), Vigamox (moxifloxacin), Zymar (gatifloxacin)
20. Therapeutic Class: Ophthalmic Antihistamines (Previous review date December 8, 2006)
Drugs Affected: Elestat (epinastine), Emadine (emedastine), ketotifen, Optivar (azelastine), Patanol (olopatadine), Pataday (olopatadine), Zaditor (ketotifen)
21. Therapeutic Class: Fluoroquinolones-Oral (Previous review date November 10, 2006)
Drugs Affected: Avelox (moxifloxacin), Cipro (ciprofloxacin), Cipro XR (ciprofloxacin ER), ciprofloxacin, ciprofloxacin ER, Factive (gemifloxacin), Floxin (ofloxacin), Levaquin (levofloxacin), Maxaquin (lomefloxacin), Noroxin (norfloxacin), ofloxacin, Proquin XR (ciprofloxacin), Tequin (gatifloxacin)
Schedule
| Time | Agenda |
|---|---|
| 8:00 - 8:15 | Welcome and Introductions |
| 8:15 - 9:45 | Public Comment Period* |
| 10:00 - 12:00 | Clinical Re-review of Bisphosphonates, Nasal Calcitonins, ACE Inhibitors, ACE Inhibitors/Diuretic, DHP CCB, ACE Inhibitors/CCB, ARBs, ARBs/Diuretic, Beta Blockers, Beta Blockers/Diuretic, Statins, Long Acting Narcotics, PPI |
| 12:00 - 1:30 | Lunch Break/Executive Session (evaluation of trade secret supplemental rebate information) |
| 1:30 - 1:45 | Final Recommendations for preferred drugs in classes reviewed in the morning session |
| 1:45 - 3:15 | Clinical Re-review of Sedative Hypnotic/Sleep Agents, Triptans, Nasal Steroids, TZDs, Triglyceride Lowering Agents, Ophthalmic Quinolones, Ophthalmic Antihistamines, Oral Fluoroquinolones |
| 3:15 - 4:15 | Afternoon Break/Executive Session (evaluation of trade secret supplemental rebate information) |
| 4:15 - 4:30 | Final Recommendations for preferred drugs reviewed in the afternoon session |
| 4:30 - 4:45 | DOH Update, Final Comments, and Adjournment |
*Interested parties must notify DOH at least one (1) week prior to the meeting of their request to address the committee during the public comment period. Requests may be made by calling 518-486-3209 or e-mailing ppno@health.state.ny.us (please reference P&T Committee). Public comments are limited to the specific topics on the agenda, must be brief (2 minutes), and the total comment period will not exceed 90 minutes. All written statements must be received at least one (1) week in advance of the meeting. Written statements should summarize key points and may not exceed two (2) pages in length.
NOTE: New clinical information must be submitted two (2) weeks prior to the date of the meeting.
Posted April 6, 2007
